Akademik Veri Yönetim Sistemi
Eurasian Journal of Medical Investigation, cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi)
Objectives: Sorafenib is frequently utilized both as first-line treatment where immunotherapies are inaccessible and as subsequent treatment in cases of progression with immunotherapy-based therapies in unresectable/metastatic HCC patients. We aim to reveal the relationship between sorafenib treatment and pancreatic atrophy. Methods: The study was designed as a retrospective, single-center study. Patients with HCC who had a CT scan within 1 month before and 6 months after treatment were included in the study. Patients receiving 6 months of sorafenib were included in the sorafenib group, while patients receiving other treatments were included in the control group. Delta (∆) value was found by subtracting the baseline pancreatic volume from the 6th month pancreatic volume. Baseline, 6-month and delta pancreatic volumes were compared between the two groups. Results: 22 patients were included in the sorafenib group and 22 patients in the control group. Delta pancreas volume was 12.69±12.96 cm3 in the sorafenib group and 1.10±2.83 cm3 in the control group and this difference was statistically significant (p<0.001). Conclusion: In our study, the incidence of pancreatic atrophy increased in sorafenib group compared to control group. Particularly in patients receiving sorafenib with prolonged survival, attention should be maintained in terms of pan- creatic atrophy.